Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-02-06
DOI
https://doi.org/10.3389/fimmu.2026.1674235
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

Yao Qi, Qing Li, Qi Deng, Jia Wang et al.
Frontiers in Immunology
CAR-T cell therapy research
article

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

Yao Qi, Qing Li, Qi Deng, Jia Wang, Xin Li, Juan Mu, Rui Cui
article en

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 17
Nankai University (CN), Tianjin First Center Hospital (CN), Tianjin Medical University (CN)
Beijing Xisike Clinical Oncology Research Foundation, Chinese Society of Clinical Oncology
Good health and well-being
Openalex Percentile: Top 64%
CAR-T cell therapy research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.